These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 36623174)
1. Natural Antibodies and Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Healthy Asymptomatic Individuals. Steele EJ; Gorczynski RM; Lindley RA; Chandra Wickramasinghe N Clin Infect Dis; 2023 May; 76(9):1697. PubMed ID: 36623174 [No Abstract] [Full Text] [Related]
2. The Natural History of Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Composite But Incomplete Picture. Sachithanandham J; Thio CL; Balagopal A Clin Infect Dis; 2021 Nov; 73(9):e2943-e2945. PubMed ID: 33090197 [No Abstract] [Full Text] [Related]
3. Severe Acute Respiratory Syndrome Coronavirus 2 Viral RNA Load Status and Antibody Distribution Among Patients and Asymptomatic Carriers in Central China. Yuan Y; Wang H; Zhao J; Jing N; Xu J; Li W; Ma B; Zhang J; Li G; Wang S; Li Y; Wang Y; Fan E; Li L Front Cell Infect Microbiol; 2021; 11():559447. PubMed ID: 33816325 [TBL] [Abstract][Full Text] [Related]
5. Dromedary camels as a natural source of neutralizing nanobodies against SARS-CoV-2. Chouchane L; Grivel JC; Farag EABA; Pavlovski I; Maacha S; Sathappan A; Al-Romaihi HE; Abuaqel SW; Ata MMA; Chouchane AI; Remadi S; Halabi N; Rafii A; Al-Thani MH; Marr N; Subramanian M; Shan J JCI Insight; 2021 Mar; 6(5):. PubMed ID: 33529170 [TBL] [Abstract][Full Text] [Related]
6. Waning Antibody Responses in Asymptomatic and Symptomatic SARS-CoV-2 Infection. Choe PG; Kang CK; Suh HJ; Jung J; Song KH; Bang JH; Kim ES; Kim HB; Park SW; Kim NJ; Park WB; Oh MD Emerg Infect Dis; 2021 Jan; 27(1):327-9. PubMed ID: 33050983 [TBL] [Abstract][Full Text] [Related]
7. Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals. Zhu Y; Yu D; Han Y; Yan H; Chong H; Ren L; Wang J; Li T; He Y Sci Adv; 2020 Nov; 6(45):. PubMed ID: 33036961 [TBL] [Abstract][Full Text] [Related]
8. The Potential of Developing Pan-Coronaviral Antibodies to Spike Peptides in Convalescent COVID-19 Patients. Rabets A; Bila G; Grytsko R; Samborskyy M; Rebets Y; Vari SG; Pagneux Q; Barras A; Boukherroub R; Szunerits S; Bilyy R Arch Immunol Ther Exp (Warsz); 2021 Mar; 69(1):5. PubMed ID: 33677719 [TBL] [Abstract][Full Text] [Related]
9. Loss of Anti-SARS-CoV-2 Antibodies in Mild Covid-19. Bölke E; Matuschek C; Fischer JC N Engl J Med; 2020 Oct; 383(17):1694-1695. PubMed ID: 32966710 [No Abstract] [Full Text] [Related]
10. Loss of Anti-SARS-CoV-2 Antibodies in Mild Covid-19. Terpos E; Mentis A; Dimopoulos MA N Engl J Med; 2020 Oct; 383(17):1695. PubMed ID: 32966711 [No Abstract] [Full Text] [Related]
11. Loss of Anti-SARS-CoV-2 Antibodies in Mild Covid-19. Kutsuna S; Asai Y; Matsunaga A N Engl J Med; 2020 Oct; 383(17):1695-1696. PubMed ID: 32966712 [No Abstract] [Full Text] [Related]
12. Loss of Anti-SARS-CoV-2 Antibodies in Mild Covid-19. Reply. Yang OO; Ibarrondo FJ N Engl J Med; 2020 Oct; 383(17):1697-1698. PubMed ID: 32966713 [No Abstract] [Full Text] [Related]
13. A Comparison of the Clinical, Viral, Pathologic, and Immunologic Features of Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS), and Coronavirus 2019 (COVID-19) Diseases. Barth RF; Buja LM; Barth AL; Carpenter DE; Parwani AV Arch Pathol Lab Med; 2021 Oct; 145(10):1194-1211. PubMed ID: 34232978 [TBL] [Abstract][Full Text] [Related]
14. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Pinto D; Park YJ; Beltramello M; Walls AC; Tortorici MA; Bianchi S; Jaconi S; Culap K; Zatta F; De Marco A; Peter A; Guarino B; Spreafico R; Cameroni E; Case JB; Chen RE; Havenar-Daughton C; Snell G; Telenti A; Virgin HW; Lanzavecchia A; Diamond MS; Fink K; Veesler D; Corti D Nature; 2020 Jul; 583(7815):290-295. PubMed ID: 32422645 [TBL] [Abstract][Full Text] [Related]
15. Anti-SARS-CoV-19 antibodies in children and adults with sickle cell disease: A single-site analysis in New York City. Green NS; Van Doren L; Licursi M; Billings DD; Sandoval LA; Feit YMZ; Hod EA Br J Haematol; 2022 Aug; 198(4):680-683. PubMed ID: 35759223 [No Abstract] [Full Text] [Related]
16. SARS CoV-2 viral load might not be the right predictor of COVID-19 mortality. Kelleni MT J Infect; 2021 Feb; 82(2):e35. PubMed ID: 32810520 [No Abstract] [Full Text] [Related]
17. Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors. Tan CW; Chia WN; Young BE; Zhu F; Lim BL; Sia WR; Thein TL; Chen MI; Leo YS; Lye DC; Wang LF N Engl J Med; 2021 Oct; 385(15):1401-1406. PubMed ID: 34407341 [TBL] [Abstract][Full Text] [Related]
18. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV. Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X MAbs; 2021; 13(1):1953683. PubMed ID: 34313527 [TBL] [Abstract][Full Text] [Related]
19. Whole Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 May Cause False-Positive Results in Serological Assays. Yamaoka Y; Jeremiah SS; Miyakawa K; Saji R; Nishii M; Takeuchi I; Ryo A Clin Infect Dis; 2021 Apr; 72(7):1291-1292. PubMed ID: 32445559 [No Abstract] [Full Text] [Related]
20. Cross-Reactive Antibodies to SARS-CoV-2 and MERS-CoV in Pre-COVID-19 Blood Samples from Sierra Leoneans. Borrega R; Nelson DKS; Koval AP; Bond NG; Heinrich ML; Rowland MM; Lathigra R; Bush DJ; Aimukanova I; Phinney WN; Koval SA; Hoffmann AR; Smither AR; Bell-Kareem AR; Melnik LI; Genemaras KJ; Chao K; Snarski P; Melton AB; Harrell JE; Smira AA; Elliott DH; Rouelle JA; Sabino-Santos G; Drouin AC; Momoh M; Sandi JD; Goba A; Samuels RJ; Kanneh L; Gbakie M; Branco ZL; Shaffer JG; Schieffelin JS; Robinson JE; Fusco DN; Sabeti PC; Andersen KG; Grant DS; Boisen ML; Branco LM; Garry RF Viruses; 2021 Nov; 13(11):. PubMed ID: 34835131 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]